Impact pathways: navigating risks in the pharmaceutical supply chain – a multi-actor perspective
通过文献综述和层次分析法，识别并优先排序了制药供应链中的15个关键风险，揭示了不同主体（如欧洲和北美）对风险优先级的差异，强调需要协作性风险管理。
Purpose This study aims to comprehensively map and prioritize risks in the pharmaceutical supply chain, focusing on European and North American countries through a multi-actor perspective. Design/methodology/approach Through a structured literature review on supply chain risk management in the pharmaceutical supply chain, we identified 84 risks. After shortlisting the 15 most critical ones, we applied the analytic hierarchy process to prioritize risks affecting the pharmaceutical supply chain, considering both the perspective of individual actors and the entire supply chain. Findings This study first analyzed the pharmaceutical supply chain risk management literature to identify the most critical risks. It then offered a novel perspective on risk prioritization through a multi-actor analytic hierarchy process, revealing how different actors assign varying levels of priority to these risks based on their unique roles and business contexts. Originality/value Recent disruptions, such as COVID-19 and the Ukraine conflict, reshaped pharmaceutical supply chain risk priorities, revealing a ranking that diverges significantly from the literature. Each supply chain actor prioritized risks differently based on their role, highlighting a fragmented approach and emphasizing the need for more collaborative, systemic risk management. This study introduces new research directions to address unmet, real-world needs within pharmaceutical supply chain risk management.